Please use this identifier to cite or link to this item:
http://bura.brunel.ac.uk/handle/2438/30891
Title: | Emerging roles of the cancerous inhibitor of protein phosphatase 2A (CIP2A) in ovarian cancer |
Authors: | Filipe, A Saravi, S Mustafov, D Panfilov, S Banger, S Mousavikivaj, S Braoudaki, M Kailasam, S Riazalhosseini, Y Sahai, MA Drenos, F Sisu, C Karteris, E |
Issue Date: | 1-Jul-2025 |
Publisher: | Springer Nature |
Citation: | Filipe, A. et al. (2025) 'From bench to bedside: emerging roles of the Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) in ovarian cancer', Scientific Reports, 15, 22382, pp. 1 - 15. doi: 10.1038/s41598-025-05013-0. |
Abstract: | Ovarian cancer (OvCa) is the sixth most common gynaecological cancer in the UK, accounting for over 200,000 deaths worldwide. Cancerous Inhibitor of Phosphatase 2 A (CIP2A) is an oncoprotein and an endogenous inhibitor of PP2A. CIP2A is a key regulator for cellular processes (e.g. proliferation, DNA damage) and is involved in the progression of many malignancies. In this study we provide a comprehensive overview of its role in OvCa making use of in silico tools, clinical samples and in vitro models. CIP2A is overexpressed in OvCa patients, with metastatic patients having significantly higher expression when compared to patients with malignant and benign ovarian tumours. High CIP2A expression reduces both overall-and progression-free survival, whereas an R530T mutation is predicted to cause structural destabilisation of the CIP2A dimer. We also provide evidence for microRNA (miRNA) and mRNA target interactions with CIP2A. Finally, we have studied the effects of CIP2A inhibition in an in vitro BRCA2 model compared to BRCA2 wild-type OvCa cells, using RNA-sequencing. Gene enrichment pointed towards changes p53 pathway, protein metabolism, transporter activity, DNA replication, and cell cycle. Our data provide a novel insight into the role of CIP2A in OvCa and the potential of drug repurposing for therapeutic interventions. |
Description: | Data availability:
The datasets generated and/or analysed during the current study are available upon reasonable request. Researchers interested in accessing the data can contact the corresponding authors. Data on DEGs is provided within the supplementary information files. Supplementary Information: The online version contains supplementary material available at https://link.springer.com/article/10.1038/s41598-025-05013-0#Sec19 . AF and SS should be considered as joint first authors. |
URI: | https://bura.brunel.ac.uk/handle/2438/30891 |
DOI: | https://doi.org/10.1038/s41598-025-05013-0 |
Other Identifiers: | ORCiD: Michelle A. Sahai https://orcid.org/0000-0002-2898-3112 ORCiD: Fotis Drenos https://orcid.org/0000-0003-2469-5516 ORCiD: Cristina Sisu https://orcid.org/0000-0001-9371-0797 ORCiD: Emmanouil Karteris https://orcid.org/0000-0003-3231-7267 Article number: 22382 |
Appears in Collections: | Dept of Life Sciences Research Papers |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
FullText.pdf | Copyright © The Author(s) 2025. Rights and permissions: Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/. | 4.71 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License